{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T17:40:29Z","timestamp":1771954829485,"version":"3.50.1"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["K23 DA044321"],"award-info":[{"award-number":["K23 DA044321"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000027","name":"National Institute on Alcohol Abuse and Alcoholism","doi-asserted-by":"publisher","award":["R01 AA021335"],"award-info":[{"award-number":["R01 AA021335"]}],"id":[{"id":"10.13039\/100000027","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofsubstanceabusetreatment.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Substance Abuse Treatment"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.jsat.2021.108455","type":"journal-article","created":{"date-parts":[[2021,4,30]],"date-time":"2021-04-30T03:40:18Z","timestamp":1619754018000},"page":"108455","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["\u201cIt could potentially be dangerous... but nothing else has seemed to help me.\u201d: Patient and clinician perspectives on benzodiazepine use in opioid agonist treatment"],"prefix":"10.1016","volume":"131","author":[{"given":"Tae Woo","family":"Park","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Sikov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanessa","family":"dellaBitta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Saitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander Y.","family":"Walley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mari-Lynn","family":"Drainoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jsat.2021.108455_bb0005","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.drugalcdep.2017.01.013","article-title":"Benzodiazepine, z-drug and pregabalin prescriptions and mortality among patients in opioid maintenance treatment\u2014A nation-wide register-based open cohort study","volume":"174","author":"Abrahamsson","year":"2017","journal-title":"Drug and Alcohol Dependence"},{"issue":"2","key":"10.1016\/j.jsat.2021.108455_bb0010","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/0749-5978(91)90020-T","article-title":"The theory of planned behavior","volume":"50","author":"Ajzen","year":"1991","journal-title":"Organizational Behavior and Human Decision Processes"},{"issue":"1","key":"10.1016\/j.jsat.2021.108455_bb0015","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1177\/0269881116675508","article-title":"Benzodiazepine maintenance in opiate substitution treatment: Good or bad? A retrospective primary care case-note review","volume":"31","author":"Bakker","year":"2017","journal-title":"Journal of Psychopharmacology (Oxford, England)"},{"issue":"2","key":"10.1016\/j.jsat.2021.108455_bb0020","doi-asserted-by":"crossref","first-page":"93","DOI":"10.31887\/DCNS.2017.19.2\/bbandelow","article-title":"Treatment of anxiety disorders","volume":"19","author":"Bandelow","year":"2017","journal-title":"Dialogues in Clinical Neuroscience"},{"issue":"9","key":"10.1016\/j.jsat.2021.108455_bb0025","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1007\/s11606-007-0251-z","article-title":"The efficacy and safety of drug treatments for chronic insomnia in adults: A meta-analysis of RCTs","volume":"22","author":"Buscemi","year":"2007","journal-title":"Journal of General Internal Medicine"},{"key":"10.1016\/j.jsat.2021.108455_bb0030","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/1471-244X-11-90","article-title":"Benzodiazepine use and misuse among patients in a methadone program","volume":"11","author":"Chen","year":"2011","journal-title":"BMC Psychiatry"},{"issue":"5","key":"10.1016\/j.jsat.2021.108455_bb0035","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1093\/fampra\/14.5.361","article-title":"Why are some doctors high-prescribers of benzodiazepines and minor opiates? A qualitative study of GPs in Norway","volume":"14","author":"Dybwad","year":"1997","journal-title":"Family Practice"},{"issue":"4","key":"10.1016\/j.jsat.2021.108455_bb0040","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.jsat.2009.03.006","article-title":"Self-perceived motivation for benzodiazepine use and behavior related to benzodiazepine use among opiate-dependent patients","volume":"37","author":"Fats\u00e9as","year":"2009","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"1\u20132","key":"10.1016\/j.jsat.2021.108455_bb0045","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0376-8716(98)00175-6","article-title":"Characteristics of benzodiazepine abuse in methadone maintenance treatment patients: A 1 year prospective study in an Israeli clinic","volume":"55","author":"Gelkopf","year":"1999","journal-title":"Drug and Alcohol Dependence"},{"issue":"8","key":"10.1016\/j.jsat.2021.108455_bb0050","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1080\/14656566.2018.1472767","article-title":"Comparing the efficacy of benzodiazepines and serotonergic anti-depressants for adults with generalized anxiety disorder: A meta-analytic review","volume":"19","author":"Gomez","year":"2018","journal-title":"Expert Opinion on Pharmacotherapy"},{"issue":"3","key":"10.1016\/j.jsat.2021.108455_bb0055","first-page":"454","article-title":"Survey of primary care and mental health prescribers\u2019 perspectives on reducing opioid and benzodiazepine co-prescribing among veterans","volume":"18","author":"Hawkins","year":"2017","journal-title":"Pain Medicine (Malden, Mass.)"},{"key":"10.1016\/j.jsat.2021.108455_bb0060","author":"Institute for Research, Evaluation, and Training in Addictions"},{"key":"10.1016\/j.jsat.2021.108455_bb0065","series-title":"Crossing the quality chasm: A new health system for the 21st century","author":"Institute of Medicine","year":"2001"},{"issue":"1","key":"10.1016\/j.jsat.2021.108455_bb0070","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/acem.13273","article-title":"Emergency department provider perspectives on benzodiazepine-opioid co-prescribing: A qualitative study","volume":"25","author":"Kim","year":"2018","journal-title":"Academic Emergency Medicine: Official Journal of the Society for Academic Emergency Medicine"},{"issue":"11","key":"10.1016\/j.jsat.2021.108455_bb0075","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002965","article-title":"Prescription of benzodiazepines, z-drugs, and gabapentinoids and mortality risk in people receiving opioid agonist treatment: Observational study based on the UK Clinical Practice Research Datalink and Office for National Statistics death records","volume":"16","author":"Macleod","year":"2019","journal-title":"PLoS Medicine"},{"key":"10.1016\/j.jsat.2021.108455_bb0080","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2296-3-9","article-title":"Long term benzodiazepine use for insomnia in patients over the age of 60: Discordance of patient and physician perceptions","volume":"3","author":"Mah","year":"2002","journal-title":"BMC Family Practice"},{"key":"10.1016\/j.jsat.2021.108455_bb0085","first-page":"338","article-title":"Factors associated with mortality in Scottish patients receiving methadone in primary care: Retrospective cohort study","author":"McCowan","year":"2009","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.jsat.2021.108455_bb0090","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1111\/j.1360-0443.2006.01731.x","article-title":"Concurrent buprenorphine and benzodiazepines use and self-reported opioid toxicity in opioid substitution treatment","volume":"102","author":"Nielsen","year":"2007","journal-title":"Addiction"},{"issue":"1","key":"10.1016\/j.jsat.2021.108455_bb0095","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1176\/appi.ps.201300419","article-title":"Datapoints: Regional variation in benzodiazepine prescribing for patients on opioid agonist therapy","volume":"65","author":"Park","year":"2014","journal-title":"Psychiatric Services"},{"issue":"5","key":"10.1016\/j.jsat.2021.108455_bb0100","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1111\/add.14886","article-title":"Associations between prescribed benzodiazepines, overdose death and buprenorphine discontinuation among people receiving buprenorphine","volume":"115","author":"Park","year":"2020","journal-title":"Addiction"},{"issue":"3","key":"10.1016\/j.jsat.2021.108455_bb0105","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.drugalcdep.2013.04.006","article-title":"Benzodiazepine use during buprenorphine treatment for opioid dependence: Clinical and safety outcomes","volume":"132","author":"Schuman-Olivier","year":"2013","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.jsat.2021.108455_bb0110","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1186\/1471-2296-14-191","article-title":"General practitioners\u2019 experiences and perceptions of benzodiazepine prescribing: Systematic review and meta-synthesis","volume":"14","author":"Sirdifield","year":"2013","journal-title":"BMC Family Practice"},{"issue":"1","key":"10.1016\/j.jsat.2021.108455_bb0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40271-016-0182-z","article-title":"A systematic review and meta-synthesis of patients\u2019 experiences and perceptions of seeking and using benzodiazepines and Z-drugs: Towards safer prescribing","volume":"10","author":"Sirdifield","year":"2017","journal-title":"The Patient"},{"key":"10.1016\/j.jsat.2021.108455_bb0120","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jsat.2017.03.002","article-title":"Beliefs about the consequences of using benzodiazepines among persons with opioid use disorder","volume":"77","author":"Stein","year":"2017","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.jsat.2021.108455_bb0125","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jsat.2016.06.008","article-title":"Reasons for benzodiazepine use among persons seeking opioid detoxification","volume":"68","author":"Stein","year":"2016","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.jsat.2021.108455_bb0130","series-title":"FDA Drug Safety Communication: FDA urges caution about withholding opioid addiction medications from patients taking benzodiazepines or CNS depressants: Careful medication management can reduce risks","author":"U.S. Food and Drug Administration","year":"2019"},{"key":"10.1016\/j.jsat.2021.108455_bb0135","author":"U.S. Food and Drug Administration"},{"issue":"4","key":"10.1016\/j.jsat.2021.108455_bb0140","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1046\/j.1440-1614.2003.01211.x","article-title":"Treatment of benzodiazepine dependence in methadone maintenance treatment patients: A comparison of two therapeutic modalities and the role of psychiatric comorbidity","volume":"37","author":"Weizman","year":"2003","journal-title":"Australian and New Zealand Journal of Psychiatry"}],"container-title":["Journal of Substance Abuse Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740547221001811?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740547221001811?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T19:54:40Z","timestamp":1760039680000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0740547221001811"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":28,"alternative-id":["S0740547221001811"],"URL":"https:\/\/doi.org\/10.1016\/j.jsat.2021.108455","relation":{},"ISSN":["0740-5472"],"issn-type":[{"value":"0740-5472","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"\u201cIt could potentially be dangerous... but nothing else has seemed to help me.\u201d: Patient and clinician perspectives on benzodiazepine use in opioid agonist treatment","name":"articletitle","label":"Article Title"},{"value":"Journal of Substance Abuse Treatment","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsat.2021.108455","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108455"}}